The Peptide Era: The Short Read

The Drug Class That Shouldn’t Have Worked

For most of the history of the modern drug industry, you did not build a company around a peptide. Proteins are the molecules that do most of the work in your body, and they’re nothing more than long chains of smaller building blocks called amino acids. A peptide is a short version of that chain: a handful of amino acids, rather than the hundreds folded up into a full protein. They’re everywhere in human biology, ferrying signals from one organ to the next. As medicines, though, they were written off as a dead end. The reasons were plain and practical.

The body treats a peptide the way it treats food. Swallow one and your gut digests it before it ever reaches the blood. Inject it instead, and the bloodstream chops it apart within minutes. The industry settled into two comfortable extremes. At one end sat small molecules, tiny chemical compounds like aspirin, cheap to manufacture and rugged enough to survive a trip through your gut. At the other came antibodies, large proteins borrowed from the immune system and turned into very precise, and very expensive, injected drugs. Peptides were stuck in the middle. Bigger and frailer than a pill. Smaller and blunter than an antibody. “Real” drugs, the thinking went, were one or the other. That consensus has collapsed, and the speed of the collapse is the real story.

The drugs that broke it are now sold under names that have become household words. Ozempic and Wegovy, two formulations of a molecule called semaglutide, from the Danish company Novo Nordisk. Mounjaro and Zepbound, two versions of a molecule called tirzepatide, from Eli Lilly. In barely five years they’ve become the fastest-growing class of medicines in the history of the pharmaceutical industry. The numbers are absurd. Ozempic alone did around $17 billion in 2024. Mounjaro about $11.5 billion. Wegovy roughly $8 billion. Novo Nordisk’s stock-market value briefly grew larger than the entire annual economic output of Denmark. And in November 2025, Eli Lilly became the first health-care company in history worth a trillion dollars.

The part most patients never hear: the molecule that cracked the field open wasn’t dreamed up in a pharmaceutical lab. It was reverse-engineered from the venom of a lizard. In the early 1990s, an endocrinologist named John Eng, working out of a Veterans Affairs hospital in the Bronx, was chasing an odd clue. Venom from the Gila monster, a heavy, slow desert lizard, seemed to enlarge the pancreas. The Gila monster eats only a few times a year, gorging and then fasting for months, all while holding its blood sugar remarkably steady. In 1992, Eng isolated the component of the venom responsible. He named it exendin-4. Lined up against the known human hormones, exendin-4 turned out to be a near-twin of a gut hormone we make ourselves, called GLP-1. The lizard’s version lasted in the bloodstream for hours instead of minutes. A synthetic copy of it became the very first drug of this class, approved in 2005 for type 2 diabetes.

A Hormone Re-engineered

To see why a lizard hormone mattered, you have to understand what GLP-1 actually does inside your own body. It’s made in the gut and released after you eat. Think of a hormone as a key and a receptor as a lock. GLP-1 fits a particular receptor on the cells of your pancreas, and when it docks, it tells those cells to release insulin. But only when blood sugar is genuinely high. That makes it a cautious, self-limiting regulator. It also acts on the brain, where it dials down appetite and signals fullness. Your body already owns an elegant machine for steadying blood sugar and curbing hunger.

The catch is that it owns it for about two minutes. An enzyme in the blood, a pair of molecular scissors called DPP-4, snips natural GLP-1 apart almost as fast as the gut can put it out. So the entire trick of these drugs is to defeat those scissors. Chemists rebuilt the hormone so the body can’t destroy it. They altered the exact spot where DPP-4 grips, so the blades slip. On the longer-acting versions, they bolted on a fatty tail that anchors the drug to proteins already drifting around in the blood, keeping it in circulation for days. A hormone that lasted ninety seconds now lasts seven days. And it took just two edits to a thirty-link chain to get there: one to blind the scissors, one to dodge the sieve.

Strip away the branding and the dollar figures, and that’s all these blockbusters are: a hormone your own gut already makes, re-engineered so the body can no longer tear it down.

Lilly’s tirzepatide goes a step further. It imitates not one gut hormone but two. The second, a partner signal called GIP, appears to deepen the effect on both blood sugar and weight. The newest drugs make a different bet. Not that you perfect the single key, but that you carry several at once. One molecule that fits two locks, or three, each belonging to a different hormone. Two levers, pulled together, beat one. The drug furthest down this path is retatrutide, a single shot, once a week, that fits all three locks at once. Its numbers are the biggest anyone has seen. In TRIUMPH-1, the phase 3 trial of more than 2,300 people with obesity that Lilly reported in May 2026, those on the highest dose lost an average of 28.3% of their body weight at 80 weeks. By the two-year mark, participants with severe obesity on the top doses were averaging over 30%. That’s territory once reached only by surgery.

One lever delivered around 15%. Two delivered above 20%. Three are now landing past 28%. Each signal you add buys another increment of weight loss.

These drugs also act on the brain, in a way patients describe more vividly than scientists do. They call it the end of food noise. The low, constant chatter about eating that runs in the background of your waking hours. What’s for lunch. There are cookies in the kitchen. You shouldn’t, but maybe just one. For many people with obesity this loop is relentless. Then they take the first injection, and within days a large share report that it simply switches off. The kitchen stops calling. A plate can sit half-eaten without protest. The drug reaches into the brain’s hunger controls and turns the volume down.

Beyond the Scale

The exciting, and slightly unsettling, part is that the same playbook is now being aimed well beyond diabetes and weight. The most consequential surprise has been the heart. In the SELECT trial, more than 17,000 people who were overweight and had heart disease but not diabetes were tracked over several years. Those on weekly semaglutide suffered about 20 percent fewer heart attacks, strokes, and deaths from heart disease than those on placebo. The benefit started showing up before participants had lost much weight. The drug protects the heart directly, not just by slimming people down. Regulators have approved it for exactly that. The same molecule has now shown protection against chronic kidney disease, against MASH (the progressive liver scarring that drives a large share of liver transplants), and against the sleep-disrupted breathing of severe obesity. That is not the profile of a fad.

Underneath the commercial fight, the science is widening on every axis at once. The race is dominated by two companies. Lilly has crossed a trillion dollars in market value. Novo Nordisk has gone the other way. By spring 2026 its value had more than halved from its peak, to around $200 billion, squeezed by competition and by pressure on U.S. drug prices. Lilly now takes an estimated 60 percent of the obesity market to Novo’s 40.

Lilly’s next bet is retatrutide. The phase 3 readouts (TRIUMPH-4 in obesity and knee osteoarthritis in December 2025, the much larger TRIUMPH-1 in obesity in May 2026) are the strongest anyone has seen from these drugs. Remaining phase 3 readouts are due later in 2026, with Lilly planning an FDA submission as soon as the end of the year. Lilly’s second bet attacks the needle. Its candidate orforglipron is a once-daily pill, and importantly, not a peptide at all. It’s a small chemical compound that survives the stomach and can be brewed cheaply by the ton. U.S. regulators approved it in April 2026.

The challengers come from a different angle. Amgen’s candidate, MariTide, which blocks the GIP signal rather than switching it on, is built for a once-monthly injection. It pulls that off by fusing the active piece to an antibody. Viking Therapeutics’ VK2735 hits the same two hormone targets as tirzepatide. Structure Therapeutics is chasing a non-peptide tablet from a different lab bench. Zealand Pharma, working with Boehringer Ingelheim, is aiming a GLP-1/glucagon drug called survodutide at fatty liver disease. Roche jumped in late 2023 by buying the startup Carmot Therapeutics for $2.7 billion. Pfizer’s path has been more painful, with two failed daily-pill candidates before it acquired the obesity startup Metsera for as much as $10 billion in November 2025.

Behind the duopoly, the next generation of drugs is taking shape. Each one is a deliberate fix to a specific limit of the first wave. Amylin combinations (cagrilintide from Novo, petrelintide from Zealand) drive about 12% weight loss on their own, but with nausea and vomiting close to placebo. Paired with GLP-1, they push total weight loss toward the top of the range while keeping patients comfortable enough to stay on it. Muscle-sparing partners like bimagrumab (which Lilly bought for nearly $2 billion in 2023) protect the muscle while the appetite drug strips the fat. And cheap daily pills plus once-monthly shots fix the reach problem of weekly injections. None of these requires a scientific miracle to land.

Beyond Metabolism

Beneath all of that sits a much larger story. The drug class is starting to look like something none of its original architects bet on, and the GLP-1 era is starting to look like the prologue to a peptide-design era that may dwarf it.

The signal pulling the field’s largest checks isn’t another weight-loss number. It’s what’s surfacing in the periphery. Places GLP-1 was never designed to reach but seems to help anyway. Each of these is asymmetric. A moonshot if it lands, nearly free to attempt because the drugs already exist and are already in tens of millions of people.

The longevity bet. GLP-1 agonists are the first commercially available drugs touching multiple hallmarks of biological aging at once. Chronic low-grade inflammation, insulin resistance, mitochondrial dysfunction, visceral fat. The mortality data is starting to make the picture concrete. A 2025 study of cancer patients on immunotherapy found GLP-1 users had a 31% lower five-year mortality. Nature Biotechnology in late 2025 framed the question driving the conversation: are GLP-1s the first longevity drugs?

The addiction bet. In March 2026, Washington University researchers published the largest dataset on the question to date. GLP-1 users had a 15–20% lower risk of developing substance use disorders across opioids, cocaine, nicotine, alcohol, and cannabis. For people already addicted, the effect was sharper. The mechanism is the same one that quiets food noise. GLP-1 reaches into the brain’s mesolimbic reward system and damps the dopamine that hijacked behavior runs on. In vervet monkey studies, semaglutide didn’t make alcohol aversive. It made it boring.

The cancer-prevention bet. A 2026 TriNetX analysis found that diabetic patients on GLP-1s had a 70–80% lower relative risk of liver cancer compared to patients on insulin. At ASCO 2026, a study reported colorectal cancer rates 36% lower in GLP-1 users than in aspirin users. Real-world data is now showing reduced metastatic progression in obesity-linked lung, breast, colorectal, and liver cancers.

The neurodegeneration bet. Novo Nordisk’s EVOKE and EVOKE+ phase 3 Alzheimer’s trials read out in 2026. The same bet (that anti-inflammatory and metabolic benefits travel into the brain) has put GLP-1 and triple-agonist drugs into Parkinson’s, ALS, and stroke-recovery trials over the past two years.

Beneath the asymmetric bets sits an even deeper shift. The drug class itself is being reinvented. Every drug to this point traces back to a molecule the body already builds. The deepest break now underway abandons that constraint entirely. Scientists have begun designing brand-new peptides from nothing, sketching on a computer a molecule that has never existed in any living thing. The approach is called de novo design. Its leading figure is David Baker, a biochemist at the University of Washington who shared the 2024 Nobel Prize in Chemistry for it. Baker’s program, RFdiffusion, starts with a formless cloud of amino acids and step by step sculpts that noise into a precise new shape, contoured to clasp whatever target the designer names. The boldest wager is Xaira Therapeutics. It launched in April 2024 with more than $1 billion in hand, among the largest sums ever raised to start a drug company. Baker is a co-founder. Drug discovery, long a matter of screening millions of compounds and hoping, is turning into a design discipline, with peptides as its first great product.

The peptide era didn’t arrive. It started. The first hit is real and proven. The second wave is already in trials. The asymmetric bets, the ones that could change what whole categories of human suffering look like, will read out over the next two or three years from drugs already in tens of millions of people. And underneath all of it, the field is learning to build peptides from scratch against targets it had spent decades calling unreachable.

A child born today will likely live in a world where treating obesity is as ordinary and durable as treating high blood pressure. Where the cravings behind addiction have a brake their doctor can prescribe. Where lower rates of heart attacks, strokes, and several major cancers are listed among the routine effects of the most prescribed drug class of their generation. And where aging itself is partly treated, rather than only endured.

That’s the prize on the table. It isn’t immortality. It’s something more humble and more sweeping: a quiet rewrite of what we accept as the background conditions of being alive.

The lizard hormone was the prologue. The book is being written now.